ProtoKinetix Seeks 20% Stock Authorization Hike to Avert Liquidation

TL;DR

**PKTX needs this share increase approved or it's game over; vote FOR if you want any chance of a return.**

AI Summary

ProtoKinetix, Inc. (PKTX) filed a DEF 14A on September 15, 2025, seeking stockholder approval to amend its Articles of Incorporation. The proposed amendment aims to increase the total number of authorized common stock shares from 500,000,000 to 600,000,000, with a par value of $0.0000053 per share. This increase is crucial for the company to raise capital through future stock sales, which will be used for working capital and general corporate purposes. As of the September 5, 2025 record date, ProtoKinetix had 389,080,152 shares outstanding, with an additional 94,790,000 shares underlying options and 8,600,000 shares underlying warrants, leaving only 1,529,848 shares available for issuance. The Board of Directors unanimously approved this action on August 29, 2025, and strongly recommends stockholders consent to avoid potential liquidation if capital cannot be raised. The consent solicitation process is being used to expedite approval and reduce costs compared to a special meeting, with an expiration date of October 5, 2025.

Why It Matters

This DEF 14A is critical for ProtoKinetix's survival, as the company explicitly states it may need to liquidate if the proposed increase in authorized shares from 500,000,000 to 600,000,000 is not approved. For investors, this means potential significant dilution if new shares are issued, but also the only clear path for the company to raise necessary capital for ongoing operations. Employees and customers face uncertainty, as the company's ability to continue operations hinges on this vote. In the competitive biotech or pharmaceutical sector, a failure to secure funding could lead to a rapid decline, impacting market sentiment for small-cap development-stage companies.

Risk Assessment

Risk Level: high — The risk level is high because the filing explicitly states, "If we do not obtain authorization to increase our number of authorized common stock, we will not be able to raise enough money to support our ongoing operations and may need to liquidate the Company." This direct threat of liquidation, coupled with only 1,529,848 shares currently available for issuance, indicates severe financial constraints.

Analyst Insight

Investors should carefully weigh the risk of significant dilution against the stated risk of company liquidation. If you believe in ProtoKinetix's long-term prospects, consenting 'FOR' the amendment is essential to keep the company operational and allow for future capital raises, despite the potential for share value dilution.

Financial Highlights

debt To Equity

N/A

revenue

$N/A

operating Margin

N/A%

total Assets

$N/A

total Debt

$N/A

net Income

$N/A

eps

$N/A

gross Margin

N/A%

cash Position

$N/A

revenue Growth

+N/A%

Executive Compensation

Key Numbers

• 500,000,000 — Current authorized common stock shares (Proposed to be increased to 600,000,000)
• 600,000,000 — Proposed authorized common stock shares (Represents a 20% increase from current authorization)
• 389,080,152 — Shares of common stock outstanding (As of the September 5, 2025 Record Date)
• 94,790,000 — Shares underlying outstanding options (Reduces available shares for issuance)
• 8,600,000 — Shares underlying outstanding warrants (Reduces available shares for issuance)
• 1,529,848 — Shares available for issuance (Extremely limited, necessitating the increase in authorized shares)
• 2025-09-05 — Record Date (For determining stockholders entitled to submit written consents)
• 2025-10-05 — Expiration Date (Deadline for receiving written consent forms by 5:00 p.m. Eastern Time)
• $0.0000053 — Par value per share (For common stock)
• 2022-02-14 — Last increase in authorized common stock (Indicates a prior need for capital raising flexibility)

Key Players & Entities

• ProtoKinetix, Inc. (company) — Registrant seeking consent solicitation
• Clarence E. Smith (person) — President and Director, Chairman, Chief Executive Officer, beneficially owns 117,987,093 shares (28.00%)
• Michael R. Guzzetta (person) — Chief Financial Officer, beneficially owns 13,996,369 shares (3.48%)
• Edward P. McDonough (person) — Director, beneficially owns 7,500,000 shares (1.89%)
• Grant Young (person) — Beneficial owner of 52,301,250 shares (12.12%)
• Alexandra Smith (person) — Beneficial owner of 27,700,776 shares (7.12%)
• John & Edith Smith (person) — Beneficial owners of 23,458,709 shares (6.03%)
• SEC (regulator) — Securities and Exchange Commission
• Nevada Revised Statutes (regulator) — Governing corporate law for ProtoKinetix
• Board of Directors (company) — Unanimously approved the Action on August 29, 2025

FAQ

Risk Factors

• Inability to Raise Capital [high — financial]: The company has only 1,529,848 shares available for issuance, which is insufficient for future capital raising needs. Failure to increase authorized shares could prevent the company from raising necessary working capital, potentially leading to liquidation.
• Dependence on Stockholder Approval [high — operational]: The proposed increase in authorized shares requires stockholder consent by October 5, 2025. A failure to obtain sufficient consent will prevent the company from executing its capital raising strategy.
• Limited Share Availability [medium — market]: With only 1,529,848 shares currently available for issuance, the company's ability to engage in future equity financing, strategic partnerships, or employee stock incentive plans is severely constrained.

Industry Context

ProtoKinetix operates in a sector that often requires significant capital for research, development, and commercialization. Companies in this space frequently rely on equity financing to fund operations and growth initiatives. The ability to access capital markets efficiently is crucial for survival and expansion, especially for smaller or development-stage firms.

Regulatory Implications

The proposed increase in authorized shares is a standard corporate governance action requiring shareholder approval under SEC regulations. The company must ensure compliance with proxy rules and disclosure requirements for the DEF 14A filing. Failure to obtain sufficient consent could trigger more stringent regulatory scrutiny or force alternative, potentially less favorable, capital-raising strategies.

What Investors Should Do

1. Review the DEF 14A filing thoroughly.
2. Submit written consent by the October 5, 2025 deadline.
3. Evaluate the company's long-term capital needs and strategy.

Key Dates

• 2025-09-15: Filing of DEF 14A — Initiated the process for stockholder approval of the increase in authorized shares.
• 2025-09-05: Record Date — Determined the stockholders eligible to submit written consents for the proposed amendment.
• 2025-10-05: Expiration Date — Deadline for stockholders to submit their written consents; critical for the company's ability to raise capital.
• 2025-08-29: Board of Directors Approval — Unanimously approved the proposed amendment to increase authorized shares.
• 2024-02-14: Last increase in authorized common stock — Indicates a historical need for capital raising flexibility, suggesting recurring capital requirements.

Glossary

DEF 14A

A filing with the U.S. Securities and Exchange Commission (SEC) that provides detailed information to shareholders regarding matters on which they are being asked to vote. (This filing outlines the proposal to increase authorized shares and seeks shareholder consent.)

Articles of Incorporation

The foundational legal document of a corporation, outlining its basic structure, purpose, and powers. (The proposed amendment to increase authorized shares requires a change to this document.)

Authorized Common Stock

The maximum number of shares of common stock that a corporation is legally permitted to issue, as specified in its Articles of Incorporation. (The core subject of this filing is to increase this limit from 500,000,000 to 600,000,000.)

Par Value

A nominal value assigned to a share of stock, often very low, used for accounting purposes and not indicative of market value. (The par value of $0.0000053 per share is relevant for the accounting of the newly authorized shares.)

Beneficial Ownership

The actual right to use or dispose of a security, even if the legal title is held by another party (e.g., a trustee). (Used to determine who controls shares, including those held by management and directors, and their percentage of ownership.)

Consent Solicitation

A process where a company seeks written consent from its shareholders to approve a corporate action, rather than holding a formal meeting. (ProtoKinetix is using this method to expedite the approval of the share authorization increase and reduce costs.)

Year-Over-Year Comparison

This DEF 14A filing focuses specifically on the proposed increase in authorized shares, a critical step for future capital raising. Unlike typical annual reports (10-K) or quarterly reports (10-Q), it does not provide a comparative financial overview of revenue, margins, or net income against the prior year. The primary comparison point is the company's current extremely limited share availability (1,529,848 shares) versus the proposed increase to facilitate future financing.

Key Financial Figures

• $0.0000053 — rized shares of common stock, par value $0.0000053 from 500,000,000 to 600,000,000. Such a

Filing Documents

• pktx_def14a.htm (DEF 14A) — 78KB
• 0001079973-25-001456.txt ( ) — 79KB

Security Ownership of Management

Security Ownership of Management As of the Record Date, the Company had 389,080,152 shares of its common stock issued and outstanding. The following table sets forth the beneficial ownership of the Company’s common stock as of the Record Date by each person who serves as a director and/or an executive officer of the Company on that date, and the number of shares beneficially owned by all of the Company’s directors and named executive officers as a group: Name and Address of Beneficial Amount and Nature of Beneficial Ownership (1) Percent of Common Stock Clarence E. Smith(2) Chairman, Chief Executive Officer, President 117,987,093 28.00 % Michael R. Guzzetta(3) Chief Financial Officer 13,996,369 3.48 % Edward P. McDonough(4) Director 7,500,000 1.89 % All current directors, directors elect, director nominees, executive officers and named executive officers as a group (three persons) 139,483,462 33.37 % Notes to Security Ownership of Management table shown above: (1) (2) Calculated in accordance with Exchange Act Rule 13d-3. Consists of 70,214,444 shares of common stock owned by Mr. Smith directly, 13,572,649 held by Mr. Smith’s trusts, 1,850,000 held by Mr. Smith’s retirement account, and the right to acquire 32,350,000 shares of common stock upon option exercise. The principal address of Mr. Smith is 1409 Peachtree Road, Daytona Beach, FL 32114. (3) Consists of 736,369 shares of common stock owned by Mr. Guzzetta directly, and 13,260,000 shares of common stock issuable upon the exercise of stock options. The principal address of Mr. Guzzetta is 1109 Poplar Ave SW, Canton, OH 44710. (4) Consists of 7,500,000 shares of common stock issuable upon the exercise of stock options. The principal business address of Mr. McDonough is 1226 Washington Avenue, Parkersburg, WV 26101.

Security Ownership

Security Ownership of Certain Beneficial Owners As of September 5, 2025, the only persons or entities that beneficially own more than 5% of its outstanding common stock who do not serve as an executive officer or director: Name and Address of Beneficial and Nature of Beneficial Percent of Common Stock Grant Young (2) 52,301,250 12.12 % Alexandra Smith (3) 27,700,776 7.12 % John & Edith Smith (4) 23,458,709 6.03 % (1) Calculated in accordance with Exchange Act Rule 13d-3. (2) Consists of 10,021,250 shares of common stock owned by Mr. Young directly; the right to acquire 6,000,000 shares of common stock upon warrant exercise; the right to acquire 36,280,000 shares of common stock upon option exercise. The principal address of Mr. Young is 6438 Rosebery Ave, West Vancouver, BC, V7W 2C6, Canada. (3) Consists of 27,700,776 shares of common stock owned by Alexandra Smith directly. The principal address of Ms. Smith is 1413 Peachtree Road, Daytona Beach, FL 32114. (4) Consists of 23,458,709 shares of common stock jointly owned by John and Edith Smith directly. The principal address of Mr. and Mrs. Smith is 4556 Arvilla Way, Friendly, WV 26146. WHERE YOU CAN OBTAIN ADDITIONAL INFORMATION We file annual, quarterly and current reports, proxy statements and other information with the SEC under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). You can read our SEC filings, including the Consent Solicitation Statement, at the SEC’s website at www.sec.gov. These reports and other information filed with the SEC by the Company may be inspected and are available for copying at the public reference facilities maintained at the Securities and Exchange Commission at 100 F Street NW, Washington, D.C. 20549. The SEC also maintains a website (http://www.sec.gov) that contains reports, proxy and information statements and other information regarding issuers that file electronically wi

View Full Filing

View this DEF 14A filing on SEC EDGAR